NewsWhore
12-18-2010, 01:30 AM
Astrazeneca's ambitions for its Brilinta drug have suffered another blow after US regulators held back their approval and asked for additional analysis of clinical trial data, delaying the launch of t...
More... (http://story.argentinastar.com/index.php/ct/9/cid/d9ed072d737073b4/id/41356763/)
More... (http://story.argentinastar.com/index.php/ct/9/cid/d9ed072d737073b4/id/41356763/)